A double-blind, randomized, placebo-controlled multi-center, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 [farglitazar] in chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy.
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Farglitazar (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 27 Oct 2008 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
- 27 Oct 2008 Actual start date changed from Oct 2005 to Nov 2005 as reported by ClinicalTrials.gov.